



Magnetic Luminex® Performance Assay Human CCL3/MIP-1 α Kit

Catalog Number: LUHM270

Pack Size: 100 Tests


SPECIFICATIONS AND USE

- Recommended Sample Types**
 - Cell culture supernates, serum, EDTA plasma, and heparin plasma.
- Microparticle Region**
 - Region-34
- Components**
 - Microparticle Concentrate (Part 894445) is supplied as a 100X concentrated stock (0.075 mL) with preservatives.
 - Biotin-Antibody Concentrate (Part 892632) is supplied as a 100X concentrated stock solution (0.075 mL) with preservatives.
- Other Supplies Required**
 - Magnetic Luminex Performance Assay Human Base Kit A (Catalog Number LUHM000).
- Storage**
 - Store the unopened kit at 2-8 °C. Do not use past the expiration date on the label.
 - Avoid freezing microparticles.**
 - Protect microparticles from light.**
- Instructions for Use**
 - Refer to the Base Kit insert for the Luminex Performance Assay procedure.

TYPICAL DATA

This human MIP-1 α standard curve is provided only for demonstration. A standard curve must be generated each time an assay is run, utilizing values from the Standard Value Card included in the Base Kit.

Note: When assaying cell culture supernate samples using Calibrator Diluent RD5K, a six-point standard curve (23-5500 pg/mL) is recommended. When assaying serum/plasma samples using Calibrator Diluent RD6-40, a six-point standard curve (67.9-16,500 pg/mL) is recommended.



| Standard | pg/mL | MFI | Average | Corrected |
|----------|--------|------------------|---------|-----------|
| Blank | 0 | 74 76 | 75 | — |
| 1 | 16,500 | 21,019 21,063 | 21,041 | 20,966 |
| 2 | 5500 | 16,739 16,900 | 16,820 | 16,745 |
| 3 | 1833 | 6566 6615 | 6591 | 6516 |
| 4 | 611 | 1634 1660 | 1647 | 1572 |
| 5 | 204 | 356 367 | 361 | 286 |
| 6 | 68 | 121 122 | 122 | 47 |

PERFORMANCE CHARACTERISTICS

All data were collected with assays run as a multiplex.

Data obtained with polystyrene and magnetic beads were equivalent.

Sensitivity - The Minimum Detectable Dose (MDD) was determined by adding two standard deviations to the MFI of twenty zero standard replicates and calculating the corresponding concentration.

Ten assays were evaluated, and the MDD of human MIP-1 α ranged from 1.25-28.3 pg/mL. The mean MDD was 8.11 pg/mL.

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

R&D Systems, Inc.

1-800-343-7475

Intra-assay Precision (precision within an assay) - Three samples of known concentration were tested twenty times on one plate to assess precision within an assay.

Inter-assay Precision (precision between assays) - Three samples of known concentration were tested in separate assays to assess precision between assays.

| | Intra-assay Precision | | | | Inter-assay Precision | | |
|--------------------|-----------------------|------|------|--|-----------------------|------|------|
| Sample | 1 | 2 | 3 | | 1 | 2 | 3 |
| n | 20 | 20 | 20 | | 11 | 11 | 10 |
| Mean (pg/mL) | 212 | 1689 | 4791 | | 181 | 1765 | 6563 |
| Standard Deviation | 22.8 | 192 | 730 | | 30 | 84 | 924 |
| % CV | 10.8 | 11.4 | 15.2 | | 16.5 | 4.8 | 14.1 |

Recovery and Linearity – Samples containing and/or spiked with high concentrations of MIP-1 α were evaluated for recovery and were serially diluted to evaluate assay linearity.

| Recovery | | | Linearity | | | | | |
|-------------------------|--------------------|-----------|-----------|-----------------------|-------------------------|--------|-------------|----------------|
| Sample Type | Average % Recovery | Range (%) | | | Cell culture supernates | Serum | EDTA Plasma | Heparin Plasma |
| Cell culture supernates | 95 | 84-104 | 1:2 | Average % of Expected | 103 | 102 | 98 | 94 |
| | | | | Range (%) | 93-122 | 93-108 | 80-112 | 79-104 |
| Serum | 106 | 95-114 | 1:4 | Average % of Expected | 103 | 95 | 99 | 94 |
| | | | | Range (%) | 83-124 | 83-101 | 81-116 | 84-109 |
| EDTA plasma | 100 | 77-111 | 1:8 | Average % of Expected | 106 | 96 | 97 | 96 |
| | | | | Range (%) | 88-121 | 83-103 | 76-116 | 83-111 |
| Heparin plasma | 112 | 104-129 | | | | | | |

Specificity - This assay recognizes natural and recombinant human MIP-1 α . The assay was tested for cross-reactivity and interference with the following factors. Less than 0.5% cross-reactivity and interference was observed.

| Recombinant human: | | | Recombinant mouse: | | Recombinant rat: | Recombinant porcine: | Recombinant human multiplex partners: | |
|--------------------|-----------------|---------------------|--------------------|----------------|------------------|----------------------|---------------------------------------|---------------|
| 6Ckine | IL-1 RII | IL-17 | G-CSF | IL-8 | GM-CSF | GM-CSF | ENA-78 | IL-6 |
| CNTF | IL-2 R α | IL-18 | GM-CSF | IL-10 | IFN- γ | IL-1 α | FGF basic | IL-8 |
| β -ECGF | IL-2 R β | LIF | IFN- γ | IL-17 | IL-1 α | IL-1 β | G-CSF | IL-10 |
| FGF acidic | IL-2 R γ | LIF R | IL-1 α | MIP-1 α | IL-1 β | IL-2 | GM-CSF | IL-17 |
| FGF-4 | IL-3 R α | MIP-1 α | IL-1ra | MIP-1 β | IL-2 | IL-4 | IFN- γ | MCP-1 |
| FGF-5 | IL-4 R | MIP-3 α | IL-1 | RANTES | IL-4 | IL-6 | IL-1 α | MIP-1 β |
| FGF-6 | IL-5 R α | MIP-3 β | IL-2 | Tpo | IL-6 | IL-8 | IL-1 β | RANTES |
| FGF-9 | IL-6 R | MCP-2 | IL-4 | TNF- α | IL-10 | IL-10 | IL-1ra | Tpo |
| FGF-10 | IL-10 R | MCP-3 | IL-5 | VEGF | TNF- α | Leptin | IL-2 | TNF- α |
| FGF-18 | IL-3 | MCP-4 | IL-6 | | | TNF- α | IL-4 | VEGF |
| GCP-2 | IL-7 | M-CSF | | | | | IL-5 | |
| GRO α | IL-9 | TNF RI | | | | | | |
| GRO β | IL-11 | TNF- α | | | | | | |
| GRO γ | IL-12 p40 | VEGF ₁₂₁ | | | | | | |
| I-309 | IL-12 p70 | VEGF ₁₆₅ | | | | | | |
| IGF-I | IL-13 | VEGF-D | | | | | | |
| IGF-II | IL-15 | | | | | | | |
| IL-1 RI | IL-16 | | | | | | | |

TECHNICAL HINTS

- Protect the microparticles and streptavidin-PE from light at all times.
- Refer to the Base Kit Standard Value Card for reconstitution volume and values of the reconstituted standard.
- Diluted microparticles cannot be stored. Make a fresh dilution of microparticles each time the assay is run.
- The use of a magnetic device made to accommodate a microplate is necessary for washing.
- Discrepancies may exist in values obtained for the same analyte utilizing different technologies.

Luminex Performance Assays afford the user the benefit of multianalyte analysis of biomarkers in a complex sample. For each sample type, a single, multipurpose diluent is used to optimize recovery, linearity, and reproducibility. Such a multipurpose diluent may not optimize any single analyte to the same degree that a unique diluent selected for analysis of that analyte can optimize conditions. Therefore, some performance characteristics may be more variable than those for assays designed specifically for single analyte analysis.